

Formulary: Rapid Access to Cancer Research Agents


The NCI Formulary, part of the Cancer Moonshot™ initiative, provides rapid access to agents with the goal of accelerating cancer research.

BY THE NUMBERS

The NCI Formulary is comprised of

27

AGENTS



including monoclonal antibodies, inhibitors, and antagonists—with more coming soon.

These agents are provided by

9

COMPANIES¹



with negotiations with other companies in process and planned.



Investigators across

300+

NCI-AUDITED SITES²

can use these agents at no cost to them.

THE BENEFITS

WHAT'S IN IT FOR THE INVESTIGATORS?



- No need to negotiate with participating companies
- Less time to acquire the agents
- Unique opportunity to obtain agent from multiple companies to combine in one study
- The distribution of agents occurs at no cost to the investigator
- Enhances the clinical trial implementation process
- Investigators own all data and publications
- Growing list of agents from collaborating companies (see nciformulary.cancer.gov)
- Suggestions welcomed for other agents that are of interest to the investigator

WHAT'S IN IT FOR THE COMPANY?



- NCI takes on the negotiation of the company approved template agreement with the audited site
- Time and cost effective option for the company to support clinical research and obtain the clinical data
- The company will be able to use the data from the studies for internal development and regulatory purposes
- Combination therapies under the Formulary allow for trials that might not otherwise be possible
- Contributing to the Formulary will also raise awareness of companies' products and current innovative research
- Company will have a pre-negotiated IP option to new inventions made with their agent

1. Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Genentech, Kyowa Kirin, Loxo Oncology, Syntrix, and Xcovery

2. NCI-audited clinical research centers include those who are the main members of NCTN and ETCTN